Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311
Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, its next-generation monoclonal antibody designed to prevent and treat...
Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, its next-generation monoclonal antibody designed to prevent and treat...
Altimmune, Inc. announced positive topline results from its Phase 2b IMPACT trial of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH)....
CRISPR Therapeutics announced updates on its in vivo cardiovascular disease programs, including new Phase 1 data for CTX310 targeting...
Pliant Therapeutics has halted the development of bexotegrast for idiopathic pulmonary fibrosis (IPF) after a Phase 2b/3 trial, BEACON-IPF,...
HCW Biologics has developed second-generation, multi-specific T-cell engagers targeting solid tumors, particularly pancreatic cancer, using its proprietary TRBC platform....
Tango Therapeutics has initiated a Phase 1/2 trial evaluating TNG462, a PRMT5 inhibitor, in combination with Revolution Medicines’ RAS...
Glucotrack, Inc. announced positive results from its first-in-human clinical study of its implantable continuous blood glucose monitor (CBGM). The...
Amneal Pharmaceuticals announced positive topline results from a Phase 3 trial of ADL-018, a biosimilar to XOLAIR® (omalizumab), developed...
Assembly Biosciences announced positive topline results from a Phase 1b study of ABI-4334, a next-generation capsid assembly modulator (CAM),...
Corvus Pharmaceuticals‘ partner in China, Angel Pharma, has received approval from the China National Medical Products Administration (NMPA) to...